G. Masterton
University of Edinburgh
17 Papers
70 Citations
G. Masterton is an academic researcher from University of Edinburgh. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 7, co-authored 11 publications. Previous affiliations of G. Masterton include NHS Lothian.
Chat about Author
Papers
Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease: REVIEW: OMEGA-3 FATTY ACIDS - A NOVEL THERAPY FOR NAFLD?
TL;DR: In this paper, the authors propose a method to improve the quality of protein-protein interactions.Aliment Pharmacol Ther 31, 679−692....
158
Circulating apoptotic and necrotic cell death markers in patients with acute liver injury.
TL;DR: The host response to cell death underpins the immune activation that follows acute liver injury, and measurement of circulating cell death markers could therefore aid prognostication following paracetamol overdose.
90
Update of endoscopy in liver disease: More than just treating varices
TL;DR: An overview of the current endoscopic management of patients with liver disease and portal hypertension is provided and the role of the endoscopist in liver disease is clear, well beyond that of just treating varices.
A case-controlled study of the safety and efficacy of transjugular intrahepatic portosystemic shunts after liver transplantation.
Andrew King,Andrew King,G. Masterton,Bridget Gunson,Bridget Gunson,Simon Olliff,Doris N. Redhead,Kamarjit Mangat,Gabriel C. Oniscu,Peter C. Hayes,Dhiraj Tripathi +10 more
TL;DR: TIPS insertion is feasible in transplant recipients, although its efficacy is lower in these patients versus control patients and outcomes are poor for OLT recipients with a pre‐TIPS MELD score > 15.
29
Coffee and the liver: a potential treatment for liver disease?
G. Masterton,Peter C. Hayes +1 more
TL;DR: Further data is urgently required particularly because of the potential to reduce fibrosis and hepatocellular carcinoma risk, which would be the first intervention of its kind to have proven benefit irrespective of etiology of liver disease.
28